Sign in
Taking people in United StatesNo phase

Comparing two surgical margin widths for removing stage 2 melanoma of the skin

Compares 1cm and 2cm skin margins when removing stage 2 melanoma in adults.

Key facts

Who runs it
Melanoma and Skin Cancer Trials Limited
Where
Albuquerque, Allentown, Ann Arbor, Atlanta, Aventura, Avon, Baltimore, Bay Shore, Bellevue, Bethlehem, Brighton, Buffalo, Burlington, Centerville, Chapel Hill, Chardon, Charleston, Charlottesville, Chicago, Cincinnati, Clackamas, Cleveland, Columbus, Coral Gables, Coral Springs, Creve Coeur, Deerfield Beach, DeKalb, Durham, Easton, Evanston, Fargo, Geneva, Gilbert, Grand Rapids, Greenville, Guilford, Hillsborough, Hollywood, Houston, Indianapolis, Irvine, Jacksonville, Kalamazoo, Kansas City, Lake Forest, Lake Success, Lakeland, Lexington, Little Rock, Livingston, Los Angeles, Madison, Marshfield, Miami, Milwaukee, Mineola, Mobile, Mount Kisco, Murray, New Haven, New York, Newport News, Oklahoma City, Omaha, Orange, Overland Park, Palo Alto, Park Ridge, Pasadena, Philadelphia, Phoenix, Piscataway, Plantation, Portland, Poughkeepsie, Quakertown, Richmond, Roanoke, Rochester, Salt Lake City, San Antonio, San Jose, Savannah, Sayre, Sioux Falls, Sleepy Hollow, Springfield, St Louis, Syracuse, Tampa, Vallejo, Walnut Creek, Warrenville, Washington D.C., Webster, West Chester, Westlake, Weston, Westwood, and Winchester, United StatesSee the 128 sitesAlso in 9 other countries, 62 sites
Trial code
Registry title
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Status
Recruiting
People taking part
2,998 people, planned
Started
17 Dec 2019
Expected to end
31 Dec 2034
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Wide Local Excision = 1cm Margin
  • Wide Local Excision = 2cm Margin
Record updated
27 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a stage II melanoma of the skin who have not yet had the wide surgery. It compares a 1 cm (0.4 in) and a 2 cm (0.8 in) cut margin.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Stage II primary invasive skin melanoma (pT2b-pT4b, AJCC 8th edition), confirmed by biopsy. A 2cm (0.8 in) margin must be technically possible. Not distal to the metacarpophalangeal joint, and no spread to nodes or distant sites.
Earlier treatment
No wide local excision yet at the melanoma site. No earlier surgery to clear the lymph nodes. Surgery must be done within 120 days of diagnosis and within 28 days of randomisation. No oral or injected immunosuppressive drugs at enrolment or in the 6 months before.

Main reasons for not taking part

  • Earlier or second invasive melanoma
  • Satellite, in-transit, regional or distant spread, or microsatellites
  • Pure desmoplastic, neurotropic or subungual melanoma
  • Another cancer in the past 5 years (some skin and cervical cancers excepted)
  • History of organ transplantation

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Patients may be included in the study if they meet ALL of the following criteria:
  • 1. Patients must have a Stage II primary invasive cutaneous melanoma (pT2b-pT4b, AJCC 8th edition) with Breslow thickness >1.0mm to 2.0mm; >2.0mm to 4.0mm or >4.0mm with ulceration, or >2.0mm to 4.0mm; or >4.0mm without ulceration (Table 1) as determined by diagnostic biopsy (narrow excision, incision, shave or punch biopsy) and subsequent histopathological analysis
  • Must have a primary melanoma that is cutaneous (including head, neck, trunk, extremity, scalp, palm or sole)
  • An uninterrupted 2cm margin must be technically feasible around biopsy scar or primary melanoma
  • 4. Surgical intervention (which refers to the staging -SLNB and WLE as these are both to be done on the same day) must be completed within 120 days of the original diagnosis. Surgical intervention must also be performed within 28 days of randomisation
  • Patients must be 18 years or older at time of consent
  • Patient must be able to give informed consent and comply with the treatment protocol and follow up plan
  • Life expectancy of at least 5 years from the time of diagnosis, not considering the melanoma in question, as determined by the PI
  • Patients must have an ECOG performance score between 0 and 1 at screening
  • A survivor of prior cancer is eligible provided that ALL of the following criteria are met and documented:; The patient has undergone potentially curative therapy for all prior malignancies,; There has been no evidence of recurrence of any prior malignancies for at least FIVE years (with the exception of successfully treated uterine/cervical or non-melanoma skin cancers (SCCs/BCCs) with no evidence of recurrence), and; The patient is deemed by their treating physician to be at low risk of recurrence from previous malignancies

Who cannot take part

  • History of previous or concurrent (i.e. >1 primary melanoma) invasive melanoma
  • Patient has undergone surgery on a separate occasion to clear the lymph nodes of the probable draining lymphatic field, including -SLNB, of the index melanoma
  • Planned adjuvant radiotherapy to the primary melanoma site after wide local excision is not permitted as part of the protocol and any patients given this treatment would be excluded from the study
  • Oral or parenteral immunosuppressive agents (not topical or inhaled steroids) at enrolment or within 6 months prior to enrolment; Pregnancy is not a specific exclusion criterion for this trial, though it may not be clinically appropriate to perform a wide excision and SLNB until the pregnancy has been completed, which may exclude the patient due to violation of inclusion criterion 4. We would advise careful counselling of the patient prior to enrolling the patient, which would include a discussion at the treating centre's multidisciplinary team meeting or tumour board. We would strongly advise contacting the central trial office to discuss the case prior to enrolling on the study
  • Uncertain diagnosis of melanoma i.e., so-called 'melanocytic lesion of unknown malignant potential'
  • Any additional solid tumour or hematologic malignancy during the past 5 years (with exception of non- melanoma skin cancers (T1 skin lesions of squamous cell carcinoma (SCCs), basal cell carcinoma (BCCs)), or uterine/cervical cancer)
  • History of organ transplantation
  • Patients will be excluded from the study for ANY of the following reasons:
  • Patient has already undergone WLE at the site of the primary index lesion
  • Patient unable or ineligible to undergo staging SLNB of the primary index lesion
  • Perineural invasion or neurotropic melanoma: Neurotropism or perineural invasion in any type of melanoma is an exclusion. Perineural invasion does not include entrapment of nerves within the main primary tumour mass
  • Desmoplastic melanoma: with any patient where pathology determines melanoma as PURE desmoplastic (as per WHO definition of >90% desmoplasia), they are not eligible for this study. However melanomas with less than 90% desmoplasia or mixed desmoplastic subtypes are eligible unless there is neurotropism present (perineural invasion)
  • Microsatellitosis (a nest of metastatic tumour cells found to be growing away from the primary tumour) as per AJCC 8th edition definition is an exclusion
  • Subungual melanoma
  • Patient has already undergone a local flap reconstruction of the defect after excision of the primary and determination of an accurate excision margin is impossible
  • Melanoma located distal to the metacarpophalangeal joint; on the tip of the nose; the eyelids or on the ear; genitalia, perineum or anus; mucous membranes or internal viscera
  • Physical, clinical, radiographic or pathologic evidence of satellite, in-transit, regional, or distant metastatic melanoma
  • Melanoma-related operative procedures not corresponding to criteria described in the protocol

Where in United States

Also in 9 other countries, 62 sites

  • Lovelace Medical Centre-Saint Joseph SquareAlbuquerque, United StatesContact: Bridget Fahy, MDTaking people
  • Lovelace Women's HospitalAlbuquerque, United StatesContact: Bridget Fahy, MDTaking people
  • St. Luke's University Health Network - Allentown Cancer CenterAllentown, United StatesContact: Darius Desai, MDTaking people
  • University of Michigan Medical CenterAnn Arbor, United StatesContact: Christina AngelesTaking people
  • Emory Saint Joseph's HospitalAtlanta, United StatesContact: Michael Lowe, MDTaking people
  • Emory UniversityAtlanta, United StatesContact: Dr Michael LoweTaking people
  • Emory University Hospital MidtownAtlanta, United StatesContact: Michael Lowe, MDTaking people
  • Northside Hospital AtlantaAtlanta, United StatesContact: Nicole KounalakisTaking people
  • Northside Hospital Cancer InstituteAtlanta, United StatesContact: Margaret FerreiraNot yet recruiting
  • University of Miami Sylvester Comprehensive Cancer Center at AventuraAventura, United StatesContact: Jessica S CrystalTaking people
  • University Hospitals Avon Health CenterAvon, United StatesContact: Luke RothermelTaking people
  • MedStar Franklin Square Medical CenterBaltimore, United StatesContact: Edward McCarronTaking people
  • Northwell Health Imbert Cancer CenterBay Shore, United StatesContact: Alan Kadison, MDTaking people
  • Nebraska Medicine-BellevueBellevue, United StatesContact: Bradley ReamesTaking people
  • St Luke's University Health Network, Bethlehem CampusBethlehem, United StatesContact: Darius DesaiTaking people
  • University of Michigan - Brighton Center for Specialty CareBrighton, United StatesContact: Christina AngelesTaking people
  • Roswell Park Cancer InstituteBuffalo, United StatesContact: Shalana O'BrienTaking people
  • University of Vermont Medical CenterBurlington, United StatesContact: Jessica Cintolo-Gonzalez, MDTaking people
  • University of Vermount and Sate Agricultural CollegeBurlington, United StatesContact: Jessica Cintolo-Gonzalez, MDTaking people
  • Miami Valley Hospital SouthCenterville, United StatesContact: James OuelletteTaking people
  • University of North Carolina at Chapel HillChapel Hill, United StatesContact: David W OllilaTaking people
  • University Hospitals Geauga Medical CenterChardon, United StatesContact: Luke RothermelTaking people
  • Medical University of South CarolinaCharleston, United StatesContact: Andrea AbbottTaking people
  • University of Virginia Health SystemCharlottesville, United StatesContact: Lynn DengelTaking people
  • Advocate Illinois Masonic Medical CenterChicago, United StatesContact: Sigrun HallmeyerTaking people
  • University of CincinnatiCincinnati, United StatesContact: Jeffrey SussmanTaking people
  • Kaiser Sunnyside Medical CenterClackamas, United StatesContact: Sandeep MashruTaking people
  • University Hospitals Cleveland Medical CentreCleveland, United StatesContact: Luke RothermelTaking people
  • Ohio State University Comprehensive Cancer CenterColumbus, United StatesContact: Joal JoalTaking people
  • University of Miami Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables, United StatesContact: Jessica S CrystalTaking people
  • University of Miami Sylvester Cancer Center at Coral SpringsCoral Springs, United StatesContact: Jessica S CrystalTaking people
  • Siteman Cancer Centre, Barnes Jewish West CountyCreve Coeur, United StatesContact: Ryan FieldsTaking people
  • University of Miami Sylvester Comprehensive Center at Deerfield BeachDeerfield Beach, United StatesContact: Jessica S CrystalTaking people
  • Northwestern Medicine Cancer Center KishwaukeeDeKalb, United StatesContact: Jeffrey WayneTaking people
  • Duke University Medical CenterDurham, United StatesContact: Jay LeeTaking people
  • St Luke's University Health Network, Anderson CampusEaston, United StatesContact: Darius DesaiTaking people
  • Northwestern UniversityEvanston, United StatesContact: Jeffrey WayneTaking people
  • Sanford Broadway Medical CentreFargo, United StatesContact: Preston SteenTaking people
  • Sanford Roger Maris Cancer CentreFargo, United StatesContact: Preston SteenTaking people
  • Northwestern Medicine Cancer Center DelnorGeneva, United StatesContact: Jeffrey WayneTaking people
  • Banner MD Anderson Cancer CenterGilbert, United StatesContact: Mark GimbelTaking people
  • Mercy Health Saint Mary'sGrand Rapids, United StatesContact: Kathleen YostTaking people
  • Spectrum Health at Butterworth CampusGrand Rapids, United StatesContact: Kathleen YostTaking people
  • East Carolina UniversityGreenville, United StatesContact: Nasreen VohraTaking people
  • Smilow Hospital Care Center, GuilfordGuilford, United StatesContact: James CluneTaking people
  • University of North Carolina Hospitals - Hillsborough CampusHillsborough, United StatesContact: David OllilaTaking people
  • University of Miami Sylvester Comprehensive Center at HollywoodHollywood, United StatesContact: Jessica S CrystalTaking people
  • The University of Texas MD Anderson Cancer CenterHouston, United StatesContact: Jeffrey GershenwaldTaking people
  • Franciscan Health IndianapolisIndianapolis, United StatesContact: Juliana MeyerTaking people
  • Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, United StatesContact: Karl BilimoriaTaking people
  • Indiana University/Melvin and Bren Simon Cancer CenterIndianapolis, United StatesContact: Karl Bilimoria, MDTaking people
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine, United StatesContact: Maki Yamamoto, MDTaking people
  • Baptist MD Anderson Cancer CenterJacksonville, United StatesContact: Konstantinos ChouliarasTaking people
  • Mayo Clinic in FloridaJacksonville, United StatesContact: James W JakubTaking people
  • West Michigan Cancer CentreKalamazoo, United StatesContact: Kathleen YostTaking people
  • University of Kansas Cancer CenterKansas City, United StatesContact: Luke SelbyTaking people
  • Northwestern Medicine Cancer Center Lake Forest HospitalLake Forest, United StatesContact: Jeffrey WayneTaking people
  • Northwell Health/Center for Advanced MedicineLake Success, United StatesContact: Alan Kadison, MDTaking people
  • Lakeland Regional Health Hollis Cancer CenterLakeland, United StatesContact: Manuel MolinaTaking people
  • University of KentuckyLexington, United StatesContact: Erin BurkeTaking people
  • University of Arkansas for Medical SciencesLittle Rock, United StatesContact: Michail MavrosTaking people
  • Cooperman Barnabas Medical CenterLivingston, United StatesContact: Adam BergerTaking people
  • Los Angeles General Medical CenterLos Angeles, United StatesContact: Gino InTaking people
  • The Angeles (Cedars-Sinai Medical Center and its Affiliates)Los Angeles, United StatesContact: Dr Mark FariesTaking people
  • USC / Norris Comprehensive Cancer CenterLos Angeles, United StatesContact: Gino InTaking people
  • University of Winsconsin Carbone Cancer Center-Eastpark medical CenterMadison, United StatesContact: Heather NeumanTaking people
  • University of Wisconsin Carbone Cancer CenterMadison, United StatesContact: Heather NeumanTaking people
  • Marshfield Medical Center-MarshfieldMarshfield, United StatesContact: Rohit SharmaTaking people
  • University of Miami Comprehensive Cancer Center at KendallMiami, United StatesContact: Jessica S CrystalTaking people
  • University of Miami Miller School of Medicine-Sylvester Cancer CentreMiami, United StatesContact: Jessica S CrystalTaking people
  • Aurora St. Luke's Medical CenterMilwaukee, United StatesContact: Sigrun HallmeyerTaking people
  • Medical College of WisconsinMilwaukee, United StatesContact: Jennifer BrueningTaking people
  • NYU Langone Medical Center (Winthrop Hospital)Mineola, United StatesContact: Erica FriedmanTaking people
  • University of South Alabama Mitchell Cancer InstituteMobile, United StatesContact: John H Howard, MDTaking people
  • Northern Westchester HospitalMount Kisco, United StatesContact: Alan KadisonTaking people
  • Intermountain Medical CenterMurray, United StatesContact: Tawnya BowlesTaking people
  • Yale UniversityNew Haven, United StatesContact: James CluneTaking people
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone HealthNew York, United StatesContact: Erica FriedmanTaking people
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Associate Professor Danielle BelloTaking people
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York, United StatesContact: Bret TabackTaking people
  • VCU Massey Cancer Center Peninsula Cancer InstituteNewport News, United StatesContact: Giao PhanTaking people
  • Mercy Health Center - Oncology HematologyOklahoma City, United StatesContact: Christian Ellis, DOTaking people
  • OUHSC Stephenson Cancer CenterOklahoma City, United StatesContact: William DooleyTaking people
  • Nebraska Medicine-Village PointeOmaha, United StatesContact: Bradley ReamesTaking people
  • University of Nebraska MedicineOmaha, United StatesContact: Bradley ReamesTaking people
  • UC Irvine Health- Chao Family Comprehensive Cancer CenterOrange, United StatesContact: Jeremy HarrisTaking people
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareOrange, United StatesContact: Maki YamamotoTaking people
  • University Hospitals Chagrin Highlands Medical CentreOrange, United StatesContact: Luke RothermelTaking people
  • University of Kansas Hospital-Indian Creek CampusOverland Park, United StatesContact: Luke SelbyTaking people
  • Stanford Cancer InstitutePalo Alto, United StatesContact: Amanda Kirane, MD FACSTaking people
  • Advocate Lutheran General HospitalPark Ridge, United StatesContact: Sigrun Hallmeyer, MDTaking people
  • Huntington Memorial HospitalPasadena, United StatesContact: Mark FariesTaking people
  • Fox Chase Cancer CenterPhiladelphia, United StatesContact: Dr Stephanie GrecoTaking people
  • Mayo Clinic PhoenixPhoenix, United StatesContact: Barbara A Pockaj, MDTaking people
  • Rutgers Cancer Institute of New JerseyPiscataway, United StatesContact: Professor Adam BergerTaking people
  • University of Miami Comprehensive Cancer Center at PlantationPlantation, United StatesContact: Jessica S CrystalTaking people
  • Kaiser Permanente Northwest - Oncology ClinicPortland, United StatesContact: Sandeep MashruTaking people
  • Vassar Brothers Medical CenterPoughkeepsie, United StatesContact: James NitzkorskiTaking people
  • St Luke's University Health Network Quakertown CampusQuakertown, United StatesContact: Darius DesaiTaking people
  • St. Luke's University Health Network - Upper BucksQuakertown, United StatesContact: Darius Desai, MDTaking people
  • VCU Massey Cancer CenterRichmond, United StatesContact: Giao PhanTaking people
  • Carilion Roanoke Memorial HospitalRoanoke, United StatesContact: Giao PhanTaking people
  • University of RochesterRochester, United StatesContact: Paul BarrTaking people
  • Huntsman Cancer Institute (The University of Utah)Salt Lake City, United StatesContact: Professor John HynstromTaking people
  • University of Texas Health Science Center at San AntonioSan Antonio, United StatesContact: Fedrico Tozzi, MDTaking people
  • Stanford Cancer Center South BaySan Jose, United StatesContact: Amanda KiraneTaking people
  • Nancy N and JC Lewis Cancer & Research Pavilion St. Joseph's/CandlerSavannah, United StatesContact: Yana Puckett, MDTaking people
  • Guthrie Medical Group PC-Robert Packer HospitalSayre, United StatesContact: David Bertsch, MDTaking people
  • Sanford Cancer Center Oncology ClinicSioux Falls, United StatesContact: Daniel Almquist, MDTaking people
  • Sanford USD Medical Center - Sioux FallsSioux Falls, United StatesContact: Daniel Almquist, MDTaking people
  • Phelps Memorial Hospital CenterSleepy Hollow, United StatesContact: Alan KadisonTaking people
  • Cox South HospitalSpringfield, United StatesContact: Srikant NannapaneniTaking people
  • Washington University School of MedicineSt Louis, United StatesContact: Ryan FieldsTaking people
  • State University of New York Upstate Medical Center-Community CampusSyracuse, United StatesContact: Daniel Thomas, MDTaking people
  • State University of New York Upstate Medical UniversitySyracuse, United StatesContact: Daniel Thomas, MDTaking people
  • Moffitt Cancer Center - Magnolia CampusTampa, United StatesContact: Jonathan ZagerTaking people
  • Moffitt Cancer Center - McKinley CampusTampa, United StatesContact: Jonathan ZagerTaking people
  • Kaiser Permanente - Vallejo Medical CenterVallejo, United StatesContact: Tatjana Kolevska, MDTaking people
  • Kaiser Permanente Walnut Creek Medical CenterWalnut Creek, United StatesContact: Tatjana Kolevska, MDTaking people
  • Northwestern Medicine Cancer Center WarrenvilleWarrenville, United StatesContact: Jeffrey WayneTaking people
  • MedStar Georgetown University HospitalWashington D.C., United StatesContact: Geoffrey T GibneyTaking people
  • MedStar Washington Hospital CenterWashington D.C., United StatesContact: Marc Boisvert, MDTaking people
  • Wilmont Cancer Institute at WebsterWebster, United StatesContact: Paul Barr, MDTaking people
  • West Chester Hospital (OH394)West Chester, United StatesContact: Jeffrey SussmanTaking people
  • University Hospitals St. John Medical CenterWestlake, United StatesContact: Luke RothermelTaking people
  • Marshfield Medical Center - WestonWeston, United StatesContact: Rohit Sharma, MDTaking people
  • University of Kansas Hospital-Westwood Cancer CenterWestwood, United StatesContact: Luke SelbyTaking people
  • VCU Massey Cancer Center Affiliate Valley HealthWinchester, United StatesContact: Giao PhanTaking people

About the trial

What the trial wants to find out

Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life.

The 2 groups in the trial

  • Arm A (Wide Local Excision = 1cm Margin)Treatment being tested

    1cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction

    Treatment: Wide Local Excision = 1cm Margin

  • Arm B (Wide Local Excision = 2cm Margin)Existing treatment, for comparison

    2 cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction

    Treatment: Wide Local Excision = 2cm Margin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Melanoma Margins Trial-II - A Phase III, Multi-centre Randomised Controlled Trial Investigating 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma (02.18 MelMarT-II)
Plain-language title
Comparing two surgical margin widths for removing stage 2 melanoma of the skinGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
27 November 2024